Project number: 2020-1.2.4-TÉT-IPARI-2021-00015
Consortium partner: Bábolna TETRA Baromfitenyésztő és Forgalmazó Kft.
Total budget: 93.004.305 HUF
Grant amount: 69.943.664 HUF
UVMB’s budget: 38.559.005 HUF
Project manager: Dr. Miklós Tenk
Duration:
from 1st January 2022. to 31st December 2024.
Summary:
The consortium plans to develop a vaccine against a disease important to poultry. Infectious poultry bronchitis (IBV) causes serious economic damage. Protocols generally recommend parenteral vaccination of laying flocks with inactivated vaccines. Vaccines containing killed pathogens are safe, but their protection is inadequate against viral diseases. Next-generation vaccines combine the two previously mentioned types of vaccines, but their production and storage costs can be very high. Inactivated vaccines do not work without immune-activating adjuvants. With the development of these molecules, the effect of conventional vaccines can be significantly enhanced. The present development is the testing of a new adjuvant in poultry, which ultimately promises an effective vaccine even in case of an average vaccine strain. The IBV strain alone is rarely used due to inadequate protection. The immunomodulatory effect of the new adjuvant has previously been demonstrated in mammals. According to the applicants, this vaccine with this strain, is also able to protect herds from infection with variant wild virus.
The Hungarian partner would investigate the role of the adjuvant as an immunomodulator. These tests could also be used to measure the effectiveness of vaccination in other diseases. The laboratory and theoretical background for this is provided by the University of Veterinary Medicine, while the birds required for clinical trials are provided by Bábolna TETRA. Their colleagues with extensive practical experience ensure that testing will be practical in large-scale conditions as well.
